KAT6A and ovarian carcinoma: To further explore whether inhibiting KAT6A activity could be an effective therapeutic strategy in ovarian cancer patients with chemoresistance, mice with A2780 xenografts received an intraperitoneal injection of cisplatin and WM-1119 at 5 mg/kg and 60 mg/kg mouse body weight, respectively.